Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study
- PMID: 28437846
- PMCID: PMC5654691
- DOI: 10.1002/acr.23266
Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study
Erratum in
-
Erratum.Arthritis Care Res (Hoboken). 2020 Apr;72(4):599. doi: 10.1002/acr.24187. Arthritis Care Res (Hoboken). 2020. PMID: 32220143 No abstract available.
Abstract
Objective: Pain sensitization may contribute to pain severity in rheumatoid arthritis (RA), impacting disease activity assessment. We examined whether pain processing mechanisms were associated with disease activity among RA patients with active disease.
Methods: The study included 139 subjects enrolled in the Central Pain in Rheumatoid Arthritis cohort. Subjects underwent quantitative sensory testing (QST), including assessment of pressure pain thresholds (PPTs) at multiple sites, conditioned pain modulation, and temporal summation. RA disease activity was assessed using the Clinical Disease Activity Index (CDAI) and its components. We examined cross-sectional associations between QST measures and disease activity using linear regression.
Results: Low PPTs (high pain sensitization) at all sites were associated with high CDAI scores (P ≤ 0.03) and tender joint counts (P ≤ 0.002). Associations between PPTs and patient global assessments were also seen at most sites. High temporal summation at the forearm (also reflecting high pain sensitization) was significantly associated with high CDAI scores (P = 0.02), patient global assessment scores (P = 0.0006), evaluator global assessment scores (P = 0.01), and tender joint counts (P = 0.02). Conversely, conditioned pain modulation (a measure of descending inhibitory pain pathways) was associated only with tender joint count (P = 0.03).
Conclusion: High pain sensitization is associated with elevations in disease activity measures. Longitudinal studies are underway to elucidate the cause-effect relationships between pain sensitization and inflammatory disease activity in RA.
© 2017, American College of Rheumatology.
Conflict of interest statement
Dr. Lee reports a research grant from Pfizer and stock in Express Scripts. Dr. Bolster reports receiving research funding from Eli Lilly. Dr. Clauw has received consulting fees from Pfizer, Eli Lilly, Nuvo, Cerephex, Tonix, Abbott, Forest Labs, Johnson & Johnson, Merck, Purdue Pharma, Sammumed, Zynerba, Astellas Pharma, Williams & Connolly LLP and Therevance. He has also received research support from Pfizer, Cypress Biosciences, Forest, Merck, Nuvo and Cerephex.
References
-
- Furu M, Hashimoto M, Ito H, Fujii T, Terao C, Yamakawa N, et al. Discordance and accordance between patient’s and physician’s assessments in rheumatoid arthritis. Scandinavian journal of rheumatology. 2014;43(4):291–5. - PubMed
-
- Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in the perception of rheumatoid arthritis disease activity. Arthritis Rheum. 2012;64:2814–23. - PubMed
-
- Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis. 2012;71(10):1702–5. - PubMed
Publication types
MeSH terms
Grants and funding
- UL1 TR000433/TR/NCATS NIH HHS/United States
- K24 AR070892/AR/NIAMS NIH HHS/United States
- R01 AR062506/AR/NIAMS NIH HHS/United States
- L30 AR065256/AR/NIAMS NIH HHS/United States
- K23 AR060241/AR/NIAMS NIH HHS/United States
- P60 AR047785/AR/NIAMS NIH HHS/United States
- P30 AR072579/AR/NIAMS NIH HHS/United States
- R01 AR064850/AR/NIAMS NIH HHS/United States
- P30 AR070254/AR/NIAMS NIH HHS/United States
- UL1 TR001102/TR/NCATS NIH HHS/United States
- P30 AR053503/AR/NIAMS NIH HHS/United States
- UL1 RR024986/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
